Levodopa/Carbidopa

Locations: 🇺🇸
University Hospitals Cleveland Medical Center (123), Cleveland, Ohio, United States
🇺🇸
Neurology Consultants of Dallas, PA (108), Dallas, Texas, United States
🇺🇸
Northwestern Medical Group Neurology Clinic (145), Chicago, Illinois, United States

and more 95 locations

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Phase 2

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Sinemet
Drug: IPX203

First Posted Date: 2017-01-02

Last Posted Date: 2022-06-06

Lead Sponsor: Impax Laboratories, LLC

Target Recruit Count: 28

Registration Number: NCT03007888

Locations: 🇺🇸
Site 114, Little Rock, Arkansas, United States
🇺🇸
Investigator 109, Cleveland, Ohio, United States
🇺🇸
Investigator 104, Spokane, Washington, United States

and more 8 locations

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Phase 1

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: Entacapone
Drug: Levodopa/carbidopa

First Posted Date: 2014-06-23

Last Posted Date: 2016-09-20

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 80

Registration Number: NCT02170376

Locations: 🇫🇷
SGS aster, Paris, France

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODM-104
Drug: Placebo
Drug: Entacapone
Drug: levodopa/carbidopa

First Posted Date: 2013-04-25

Last Posted Date: 2015-04-01

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 101

Registration Number: NCT01840423

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODM103
Drug: Placebo
Drug: Entacapone
Drug: Levodopa/carbidopa

First Posted Date: 2012-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 67

Registration Number: NCT01688089

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Vision Response to Dopamine Replacement

Phase 2

Terminated

Conditions: Albinism
Oculocutaneous Albinism

Interventions: Drug: Levodopa/carbidopa

First Posted Date: 2012-08-14

Last Posted Date: 2019-06-11

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 20

Registration Number: NCT01663935

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: Levodopa/Carbidopa
Drug: Levodopa/Benzerazide

First Posted Date: 2012-04-02

Last Posted Date: 2015-12-24

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 40

Registration Number: NCT01568047

Locations: 🇺🇦
Ukrainian State Scientific Research Institute of Medical and Social Problems of Disability, Department of Neurology and Adjustment Conditions, Dnipropetrovsk, Ukraine
🇺🇦
Department of Neuroinfections and multiple sclerosis, SI "Institute of Neurology, Psychiatry and Narcology of AMS of Ukraine, Kharkiv, Ukraine
🇺🇦
Department No. 23 of Communal setting of medical care Kharkiv's regional clinical psychiatric hospital No. 3,, Kharkiv, Ukraine

and more 4 locations

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: Levodopa/Carbidopa
Drug: Levodopa/Benzerazide

First Posted Date: 2012-04-02

Last Posted Date: 2015-01-12

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 10

Registration Number: NCT01568034

Locations: 🇺🇦
Department of Neurology- Hospital of the department of medical care of Ministry Internal Affairs of Ukraine, Kyiv, Ukraine
🇵🇹
Department of Neurology-Hospital de Santa Maria-Faculty of Medicine, University of Lisbon, Lisbon, Portugal
🇷🇴
Spitalul Clinic Colentina - Clinica de Neurologie, Bucharest, Romania

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: levodopa/carbidopa
Drug: levodopa/benserazide

First Posted Date: 2012-02-15

Last Posted Date: 2015-11-16

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 52

Registration Number: NCT01533116

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy